BeOne Medicines Aktie
| 0,00EUR | 0,00EUR | 0,00% |
WKN DE: A41ANK / ISIN: CH1391448177
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 5 300 | 8 200 | 9 000 | 10 000 | 11 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,45 | 1,12 | 1,23 | 1,92 | 2,70 |
Bilanz (in Mio. HKD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 38 464 | 59 360 | 40 641 | 32 823 | 31 006 |
| Summe Anlagevermögen | 4 963 | 8 046 | 9 149 | 12 508 | 15 020 |
| Summe Aktiva | 43 427 | 67 406 | 49 790 | 45 331 | 46 026 |
Bilanz (in Mio. HKD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 13 426 | 18 734 | 15 578 | 17 709 | 20 141 |
| Summe Eigenkapital | 30 002 | 48 672 | 34 212 | 27 621 | 25 885 |
| Summe Passiva | 43 427 | 67 406 | 49 790 | 45 331 | 46 026 |
Adresse
| Aeschengraben 27, 4051 Basel | |
| Telefon | +41 (61) 685-19-00 |
| Internet | http://beonemedicines.com |
Management
|
Aaron Rosenberg
Chief Financial Officer |
|
Alessandro Riva
Independent Non-Executive Director |
|
Anthony C. Cooper
Director |
|
Anthony C. Hooper
Independent Non-Executive Director |
|
Chan Lee
Secretary, Senior Vice President & General Counsel |
|
Clare Fisher
Senior VP-Business Development & Licensing |
|
Corazon Dating Sanders
Independent Non-Executive Director |
|
Eva Yin
Chief Commercial Officer |
|
Giancarlo Benelli
Senior Vice President & Head-Europe |
|
Graham Hardiman
Global Head-Human Resources & Senior VP |
|
Han Ma
Chief Safety Officer & SVP-al Patient Safety |
|
Jason W. Radford
Senior VP-Strategy & Corporate Development |
|
John V. Oyler
Chairman & Chief Executive Officer |
|
Julie Lepin
Chief Regulatory Affairs Officer & Senior VP |
|
Julius Pryor
Global Head-Diversity & Health Equity |
|
Kyu-Sung Lee
SVP, Head-Technical Operations & Manufacturing |
|
Lai Wang
Global Head-Research & Development |
|
Liza Heapes
Investor Relations Contact |
|
Marcello Damiani
Chief Technology Officer |
|
Margaret Han Dugan
Independent Non-Executive Director |
|
Mark Lanasa
Chief Medical Officer-Solid Tumors & SVP |
|
Michael J. Goller
Independent Non-Executive Director |
|
Olivier Brandicourt
Independent Non-Executive Director |
|
Qing Qing Yi
Independent Non-Executive Director |
|
Ranjeev Krishana
Lead Independent Director |
|
Shalini Sharp
Independent Non-Executive Director |
|
Titus Benjamin Ball
Chief Accounting Officer & Vice President |
|
Xiao Bin Wu
President, Chief Operating Officer & GM-China |
|
Xiao Dong Wang
Non-Executive Director |
|
Yan Liu
Vice President-Marketing |
|
Yang Ji
Chief Compliance Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.